Skip to main content
Top
Published in: Internal and Emergency Medicine 1/2010

01-10-2010 | Symposium: Chronicisation of Headaches. Natural Evolution, Drugs Dependence and Rehabilitation

Chronic migraine: comorbidities, risk factors, and rehabilitation

Authors: Andrea Negro, Lidia D’Alonzo, Paolo Martelletti

Published in: Internal and Emergency Medicine | Special Issue 1/2010

Login to get access

Abstract

Migraine is a serious illness with a spontaneous clinical evolution into a chronic form. In some episodic migraines, increase of crises frequency modifies the headache pattern in the chronic form, defined as chronic migraine (CM), with headache frequency of 15 days/month. One-year prevalence of CM includes around 2–4% of the general population. Migraine progression from episodic to chronic form is realized through a period of time involving several months or years, during which an increase of attack frequency occurs. Migraine shows a wide spectrum of comorbidities, including cardiocerebral, vascular, psychiatric, metabolic, neurologic as well as other pathologies. The single/multiple presence of such comorbidities represents a fixed factor in the process of chronicization into CM. Risk factors including medication overuse headache (MOH), obesity, and lifestyle cooperate in the evolution process to CM. MOH is the most severe complication of CM, and similarly to CM its appearance is gradual. Both CM and MOH show particular genetic background able to favor the appearance of chronicity and abuse. Rehabilitation consists of drug withdrawal procedures, re-prophylaxis through administration of innovative drugs, such as OnabotulinumtoxinA and/or topiramate, to avoid relapsing attacks, and behavioral strategies to minimize the role of risk factors. The initial relief step for drug abusers always relies in drug withdrawal. The feasible diagnostic setting for a CM tailored treatment based on the application of pharmacogenomics will allow us to predetermine the efficacy of single old and new drugs by avoiding abuse due to non-responsivity of the acute drug.
Literature
1.
go back to reference Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746CrossRefPubMed Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746CrossRefPubMed
3.
go back to reference Silberstein S, Olesen J, Bousser MG et al (2005) The international classification of headache disorders, 2nd edn (ICHD-II). Revised of criteria for 8.2 medication-overuse headache. Cephalalgia 25:460–465 Silberstein S, Olesen J, Bousser MG et al (2005) The international classification of headache disorders, 2nd edn (ICHD-II). Revised of criteria for 8.2 medication-overuse headache. Cephalalgia 25:460–465
4.
go back to reference Allena M, Katsarava Z, Nappi G, the COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 10:71–76CrossRefPubMed Allena M, Katsarava Z, Nappi G, the COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 10:71–76CrossRefPubMed
5.
go back to reference Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol 9:391–401CrossRefPubMed Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication overuse headache. Lancet Neurol 9:391–401CrossRefPubMed
6.
go back to reference Rossi P, Jensen R, Nappi G, Allena M, the COMOESTAS Consortium (2009) A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 10:407–417CrossRefPubMed Rossi P, Jensen R, Nappi G, Allena M, the COMOESTAS Consortium (2009) A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 10:407–417CrossRefPubMed
7.
go back to reference Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276CrossRefPubMed Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? Curr Opin Neurol 22:269–276CrossRefPubMed
8.
go back to reference Pompili M, Serafini G, Di Cosimo D, Innamorati M, Lester D, Forte D, Girardi N, De Filippis S, Tatarelli R, Martelletti P (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 6:81–91CrossRefPubMed Pompili M, Serafini G, Di Cosimo D, Innamorati M, Lester D, Forte D, Girardi N, De Filippis S, Tatarelli R, Martelletti P (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 6:81–91CrossRefPubMed
9.
go back to reference Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10:283–290CrossRefPubMed Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10:283–290CrossRefPubMed
10.
go back to reference Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63–65CrossRefPubMed Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63–65CrossRefPubMed
11.
go back to reference Kurth T (2007) Migraine and ischaemic vascular events. Cephalalgia 27:967–975CrossRef Kurth T (2007) Migraine and ischaemic vascular events. Cephalalgia 27:967–975CrossRef
12.
go back to reference Tzourio C, Tehindrazanarivelo A, Iglesias S et al (1995) Case–control study of migraine and risk of ischaemic stroke in young women. BMJ 310:830–833PubMed Tzourio C, Tehindrazanarivelo A, Iglesias S et al (1995) Case–control study of migraine and risk of ischaemic stroke in young women. BMJ 310:830–833PubMed
13.
go back to reference Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case–control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Br Med J 318:13–18 Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case–control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Br Med J 318:13–18
14.
go back to reference Kurth T, Gaziano JM, Cook NR et al (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291CrossRefPubMed Kurth T, Gaziano JM, Cook NR et al (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291CrossRefPubMed
15.
go back to reference Stang PE, Carson AP, Rose KM et al (2005) Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64:1573–1577CrossRefPubMed Stang PE, Carson AP, Rose KM et al (2005) Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64:1573–1577CrossRefPubMed
16.
go back to reference Kruit MC, van Buchem MA, Hofman PAM et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427–434CrossRefPubMed Kruit MC, van Buchem MA, Hofman PAM et al (2004) Migraine as a risk factor for subclinical brain lesions. JAMA 291:427–434CrossRefPubMed
17.
go back to reference Spector JJ, Kahn SR, Jones SR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123:612–634CrossRefPubMed Spector JJ, Kahn SR, Jones SR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123:612–634CrossRefPubMed
18.
go back to reference Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339:b3914CrossRefPubMed Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 339:b3914CrossRefPubMed
19.
go back to reference Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease. A population-based study. Neurology 74:628–635CrossRefPubMed Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease. A population-based study. Neurology 74:628–635CrossRefPubMed
20.
go back to reference Schwedt TJ (2009) The migraine association with cardiac anomalies, cardiovascular disease and stroke. Neurol Clin 27:513–523CrossRefPubMed Schwedt TJ (2009) The migraine association with cardiac anomalies, cardiovascular disease and stroke. Neurol Clin 27:513–523CrossRefPubMed
21.
go back to reference Dalla Volta G, Guindani M, Zavarise P et al (2005) Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain 6:328–330CrossRefPubMed Dalla Volta G, Guindani M, Zavarise P et al (2005) Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain 6:328–330CrossRefPubMed
22.
go back to reference Ferrarini G, Malferrari G, Zucco R et al (2005) High prevalence of patent foramen ovale in migraine with aura. J Headache Pain 6:71–76CrossRefPubMed Ferrarini G, Malferrari G, Zucco R et al (2005) High prevalence of patent foramen ovale in migraine with aura. J Headache Pain 6:71–76CrossRefPubMed
23.
go back to reference Tembl J, Lago A, Sevilla T et al (2007) Migraine, patent foramen ovale and migraine triggers. J Headache Pain 8:7–12CrossRefPubMed Tembl J, Lago A, Sevilla T et al (2007) Migraine, patent foramen ovale and migraine triggers. J Headache Pain 8:7–12CrossRefPubMed
24.
go back to reference Jesurum JT, Fuller CJ, Velez CA et al (2007) Migraineurs with patent foramen ovale have larger right-to left shunt despite similar atrial septal characteristics. J Headache Pain 8:209–216CrossRefPubMed Jesurum JT, Fuller CJ, Velez CA et al (2007) Migraineurs with patent foramen ovale have larger right-to left shunt despite similar atrial septal characteristics. J Headache Pain 8:209–216CrossRefPubMed
25.
go back to reference Wilmshurst PT, Nightingale S, Walsh KP et al (2005) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke for haemodynamic reasons. Lancet 356:1648–1651CrossRef Wilmshurst PT, Nightingale S, Walsh KP et al (2005) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke for haemodynamic reasons. Lancet 356:1648–1651CrossRef
26.
go back to reference Azarbal B, Tobis J, Suh W et al (2005) Association of interatrial shunts and migraine headaches. J Am Coll Cardiol 45:489–492CrossRefPubMed Azarbal B, Tobis J, Suh W et al (2005) Association of interatrial shunts and migraine headaches. J Am Coll Cardiol 45:489–492CrossRefPubMed
27.
go back to reference Thenganatt J, Schneiderman J, Hyland RH et al (2006) Migraines linked to intrapulmonary right-to-left shunt. Headache 46:439–443CrossRefPubMed Thenganatt J, Schneiderman J, Hyland RH et al (2006) Migraines linked to intrapulmonary right-to-left shunt. Headache 46:439–443CrossRefPubMed
28.
go back to reference Litman GI, Friedman HM (1978) Migraine and the mitral valve prolapse syndrome. Am Heart J 96:610–614CrossRefPubMed Litman GI, Friedman HM (1978) Migraine and the mitral valve prolapse syndrome. Am Heart J 96:610–614CrossRefPubMed
29.
go back to reference Spence JD, Wong DG, Melendez LJ et al (1984) Increased prevalence of mitral valve prolapse in patients with migraine. Can Med Assoc J 131:1457–1460PubMed Spence JD, Wong DG, Melendez LJ et al (1984) Increased prevalence of mitral valve prolapse in patients with migraine. Can Med Assoc J 131:1457–1460PubMed
30.
go back to reference Carerj S, Narbone MC, Zito C et al (2003) Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 43:725–728CrossRefPubMed Carerj S, Narbone MC, Zito C et al (2003) Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 43:725–728CrossRefPubMed
31.
go back to reference Truong T, Slavin L, Kashani R et al (2008) Prevalence of migraine headaches in patients with congenital heart disease. Am J Cardiol 101:396–400CrossRefPubMed Truong T, Slavin L, Kashani R et al (2008) Prevalence of migraine headaches in patients with congenital heart disease. Am J Cardiol 101:396–400CrossRefPubMed
32.
go back to reference Innamorati M, Pompili M, De Filippis S, Gentili F, Erbuto D, Lester D, Tamburello A, Iacorossi G, Cuomo I, Dominici G, Tatarelli R, Martelletti P (2009) The validation of the Italian perceived disability scale (IPDS) in chronic daily headache sufferers. J Headache Pain 10:21–26CrossRefPubMed Innamorati M, Pompili M, De Filippis S, Gentili F, Erbuto D, Lester D, Tamburello A, Iacorossi G, Cuomo I, Dominici G, Tatarelli R, Martelletti P (2009) The validation of the Italian perceived disability scale (IPDS) in chronic daily headache sufferers. J Headache Pain 10:21–26CrossRefPubMed
33.
go back to reference Oedegaard KJ, Angst J, Neckelmann D, Fasmer OB (2005) Migraine aura without headache compared to migraine with aura in patients with affective disorders. J Headache Pain 6:378–386CrossRefPubMed Oedegaard KJ, Angst J, Neckelmann D, Fasmer OB (2005) Migraine aura without headache compared to migraine with aura in patients with affective disorders. J Headache Pain 6:378–386CrossRefPubMed
34.
go back to reference Franchini L, Bongiorno F, Dotoli D, Rainero I, Pinessi L, Smeraldi E (2004) Migraine headache and mood disorders: a descriptive study in an out-patient psychiatric population. J Affect Disord 81:157–160CrossRefPubMed Franchini L, Bongiorno F, Dotoli D, Rainero I, Pinessi L, Smeraldi E (2004) Migraine headache and mood disorders: a descriptive study in an out-patient psychiatric population. J Affect Disord 81:157–160CrossRefPubMed
35.
go back to reference Cuvellier JC, Carvalho S, Mars A, Auvin S (2009) Study on management of pediatric migraine by general practitioners in northern France. J Headache Pain 10:167–175CrossRefPubMed Cuvellier JC, Carvalho S, Mars A, Auvin S (2009) Study on management of pediatric migraine by general practitioners in northern France. J Headache Pain 10:167–175CrossRefPubMed
36.
go back to reference Cuvellier JC, Donnet A, Guégan-Massardier E, Nachit-Ouinekin F, Parain D, Vallée L (2009) Treatment of primary headache in children: a multicenter hospital-based study in France. J Headache Pain 10:447–453CrossRefPubMed Cuvellier JC, Donnet A, Guégan-Massardier E, Nachit-Ouinekin F, Parain D, Vallée L (2009) Treatment of primary headache in children: a multicenter hospital-based study in France. J Headache Pain 10:447–453CrossRefPubMed
37.
go back to reference Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P (2010) Patient outcome in migraine prophylaxis: the role of psycopharmacological agents. Patient Relat Outcome Meas 1:1–12 Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P (2010) Patient outcome in migraine prophylaxis: the role of psycopharmacological agents. Patient Relat Outcome Meas 1:1–12
38.
go back to reference Villani V, Bruti G, Mostradini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R (2005) Migraine in the Emergency Department: a psychometric study of a migraine “repeaters” sample. J Headache Pain 6:301–303CrossRefPubMed Villani V, Bruti G, Mostradini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R (2005) Migraine in the Emergency Department: a psychometric study of a migraine “repeaters” sample. J Headache Pain 6:301–303CrossRefPubMed
39.
go back to reference De Filippis S, Erbuto D, Gentili F, Innamorati M, Lester D, Tatarelli R, Martelletti P, Pompili M (2008) Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain 9:349–357CrossRefPubMed De Filippis S, Erbuto D, Gentili F, Innamorati M, Lester D, Tatarelli R, Martelletti P, Pompili M (2008) Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain 9:349–357CrossRefPubMed
40.
go back to reference Vargas BB, Dodick DW (2009) The face of chronic migraine: epidemiology, demographics and treatment strategies. Neurol Clin 27:467–479CrossRefPubMed Vargas BB, Dodick DW (2009) The face of chronic migraine: epidemiology, demographics and treatment strategies. Neurol Clin 27:467–479CrossRefPubMed
41.
go back to reference Buse DC, Marcia FT, Rupnow FT, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422–435CrossRefPubMed Buse DC, Marcia FT, Rupnow FT, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422–435CrossRefPubMed
42.
go back to reference Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how we can prevent relapse? Int Emerg Med. doi:10.1007/s11739-010-0410-9 Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how we can prevent relapse? Int Emerg Med. doi:10.​1007/​s11739-010-0410-9
43.
go back to reference Trucco M, Meineri P, Ruiz L, on behalf of the “gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee” (Neurological Hospital Interregional Group for the Study of Headaches) (2010) Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 6:334–337CrossRef Trucco M, Meineri P, Ruiz L, on behalf of the “gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee” (Neurological Hospital Interregional Group for the Study of Headaches) (2010) Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 6:334–337CrossRef
44.
go back to reference Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. doi:10.1007/s10194-010-0221-4 Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. doi:10.​1007/​s10194-010-0221-4
46.
go back to reference Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opin Neurol 23:254–258CrossRefPubMed Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opin Neurol 23:254–258CrossRefPubMed
47.
go back to reference Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 7:407–412CrossRefPubMed Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 7:407–412CrossRefPubMed
48.
go back to reference Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Trial. (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803CrossRefPubMed Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Trial. (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803CrossRefPubMed
49.
go back to reference Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, on behalf of the PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRefPubMed Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, on behalf of the PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRefPubMed
50.
go back to reference Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF, on behalf of the PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Pooled a results from the double-blind, randomized, placebo-controlled phases of the PREEMPT Clinical Program. Headache 50:921–936CrossRefPubMed Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF, on behalf of the PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: Pooled a results from the double-blind, randomized, placebo-controlled phases of the PREEMPT Clinical Program. Headache 50:921–936CrossRefPubMed
51.
52.
53.
go back to reference Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Int Emerg Med 4:367–373CrossRef Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Int Emerg Med 4:367–373CrossRef
54.
go back to reference Mathew NT, Farhan AJ (2009) A double-blind comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466–1478CrossRefPubMed Mathew NT, Farhan AJ (2009) A double-blind comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466–1478CrossRefPubMed
55.
go back to reference Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P (2010) Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 11:151–156CrossRefPubMed Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P (2010) Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 11:151–156CrossRefPubMed
56.
go back to reference Di Lorenzo C, Di Lorenzo G, Sances G et al (2009) Drug consumption in medication overuse headache is influenced by brain derived neurotrophic factor Val66Met polymorphism. J Headache Pain 10:349–355CrossRefPubMed Di Lorenzo C, Di Lorenzo G, Sances G et al (2009) Drug consumption in medication overuse headache is influenced by brain derived neurotrophic factor Val66Met polymorphism. J Headache Pain 10:349–355CrossRefPubMed
57.
go back to reference Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9:1267–1269CrossRefPubMed Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9:1267–1269CrossRefPubMed
58.
go back to reference Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. doi:10.1007/s10194-010-0241-0 Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. doi:10.​1007/​s10194-010-0241-0
Metadata
Title
Chronic migraine: comorbidities, risk factors, and rehabilitation
Authors
Andrea Negro
Lidia D’Alonzo
Paolo Martelletti
Publication date
01-10-2010
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue Special Issue 1/2010
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-010-0457-7

Other articles of this Special Issue 1/2010

Internal and Emergency Medicine 1/2010 Go to the issue

Symposium: Chronicisation of Headaches. Natural Evolution, Drugs Dependence and Rehabilitation

Chronic headaches and medication overuse

Symposium: Managing of Complications in Patients with Cancer

Infectious complications in neutropenic cancer patients

Selected Paper: Gut Microbiota and Related Diseases

RETRACTED ARTICLE: Gut microbiota and related diseases: clinical features

Symposium: Managing of Complications in Patients with Cancer

Management of cancer pain

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.